SLC6A3 and Parkinson disease: The Bäckman research team, through longitudinal DAT-SPECT tracking, found that PD patients with an annual striatal DAT binding decline rate exceeding 5% had a 3.2-fold increased risk of progression to MCI within 3 years, indicating that DAT loss could serve as an early predictive biomarker of cognitive decline (19).